



Horizon Europe

Evaluation Form (HE EIC Accelerator)

Version 1.0
18 June 2021



**SENSITIVE**

[INDIVIDUAL EVALUATION REPORT (IER)]**[CONSENSUS REPORT (CR)]**
[EVALUATION SUMMARY REPORT]


PROJECT	
Project number:	[project number]
Project name:	[project title]
Project acronym:	[acronym]
Coordinator contact:	[PCoCo name NAME], [organisation]
Call:	[call ID]
Topic:	[topic ID]
Type of action:	[ToA ID]
Responsible service:	[responsible unit, e.g. JUST/04]
Project duration:	[number of months]


PARTICIPANTS					
Number	Role	Short name	Legal name	Country	PIC
1	COO				
2	BEN				
2.1	AE				
3	BEN				
4	AP				

<p>PROJECT ABSTRACT</p> <p><i>Text from Proposal Abstract (Application Form Part A).</i></p>

EVALUATION	
Evaluation model:	[single] [step 1] [step 2]
Panel:	[insert panel identifier]
Evaluators:	[name NAME], [name NAME], [name NAME]

1. EVALUATION

 Applications **must be evaluated as they were submitted**, NOT on their potential if certain changes were made. Therefore, do NOT recommend any modifications (e.g. consortia composition, resources or budget, or inclusion of additional work packages).

 If an application is partly out of scope, this should be reflected in the comments.

<p>1. Excellence</p> <p>The following aspects will be taken into account, to the extent that the proposed work corresponds to the description in the work programme:</p> <ul style="list-style-type: none"> • Breakthrough and market creating nature: Does the innovation have a high degree of novelty – compared to existing products, services and business models – with the potential to create or significantly disrupt markets? • Timing: Is the timing right for this innovation in terms of market, user, societal or scientific or technological trends and developments? • [OPTION for full application only: Technological feasibility: Is the innovation based on a technology or technologies that have been adequately assessed at least in a laboratory environment and relevant environments to characterise the potential and assess the level of risk (at least TRL 5/6)? • Intellectual Property: Does your company have the necessary Intellectual Property Rights to ensure freedom to operate and adequate protection of the idea?]
<p>Comments:</p>
<p>2. Impact</p> <p>The following aspects will be taken into account, to the extent that the proposed work corresponds to the description in the work programme:</p> <ul style="list-style-type: none"> • Scale up potential: Does the innovation have scale up potential, including the potential to develop new markets and impact on the growth of the company? Are the associated financial needs well assessed and realistic?

- **Broader impact:** Will the innovation, if successfully commercialised achieve broader societal, economic, environmental¹ or climate impacts?¹
- **[OPTION for full application only: Market fit and competitor analysis:** Has the potential market for the innovation been adequately assessed, including conditions and growth rates? Has a competitive analysis been thoroughly performed, including identification of potential customers and users, definition of unique selling points and key differentiation from competitors?
- **Commercialisation strategy:** Is there a convincing and well thought-through strategy for commercialisation, including regulatory approvals/compliance needed, time to market/deployment, and business and revenue model?
- **Key partners:** Have the key partners required to develop and commercialise the innovation been identified and engaged, including their roles/competences and a sufficient level of commitment and incentivisation?]
- **[OPTION for full application of Accelerator Challenges:** Strategic Impact on Digital or Health Technologies: Does the innovation have the potential to be a strategically important technology for Europe, in terms of welfare of citizens or relevance to economic development? .]

Comments:

--	--


- 3. Level of risk, implementation, and need for Union support**
- The following aspects will be taken into account, to the extent that the proposed work corresponds to the description in the work programme:
- **Team:** Does the team have the capability and motivation to implement the innovation proposal and bring it to the market? Is there a plan to acquire any critical competencies which are currently missing?
 - **[OPTION for full application only: Milestones:** Is there a clear implementation plan with defined milestones, work packages and deliverables, together with realistic resources and timings?
 - **Risk level of the investment:** Does the nature and level of risk of the investment in your innovation mean that market actors are unwilling to commit the full amount alone? Is there evidence that market actors would be willing to invest, either alongside the EIC or at a later stage?
- Note: Small mid-caps will be expected to provide documentary evidence that their bank has refused the financing needed for the project.
- **Risk mitigation:** Have the main risks been identified, together with measures to take to mitigate them?]

Comments:

--	--

¹ Projects must comply with the ‘do no significant harm’ principle of the EU Sustainable Finance Taxonomy

2. OTHER QUESTIONS

Opinion on additional questions
<p>Scope of the application</p> <p>Based on the information provided, this application is:</p> <p><input type="radio"/> 'in scope' because it corresponds, wholly or in part, to the topic description against which it has been submitted</p> <p><input type="radio"/> 'out of scope' because: <input type="text" value="[Comment box]"/></p>
<p>Exceptional funding</p> <p> A third country participant/international organisation not listed in the General Annex to the Main Work Programme may exceptionally receive funding if their participation is essential for carrying out the project (for instance due to outstanding expertise, access to unique know-how, access to research infrastructure, access to particular geographical environments, possibility to involve key partners in emerging markets, access to data, etc.). (For more information, see the HE programme guide)</p> <p><i>Please list the concerned applicants and requested grant amount and explain the reasons why.</i></p> <p>Based on the information provided, the following participants should receive exceptional funding: <input type="text" value="[Comment box]"/></p> <p>Based on the information provided, the following participants should NOT receive exceptional funding: <input type="text" value="[Comment box]"/></p>
<p>Use of human embryonic stem cells (hESC)</p> <p>Does this proposal involve the use of hESC?</p> <p><input type="radio"/> No</p> <p><input type="radio"/> Yes</p> <p><i>If YES, please state whether the use of hESC is, or is not, in your opinion, necessary to achieve the scientific objectives of the proposal and the reasons why. Alternatively, please state if it cannot be assessed whether the use of hESC is necessary or not, because of a lack of information.</i></p> <p><input type="text" value="[Comment box]"/></p>
<p>Use of human embryos</p> <p>Does this proposal involve the use of human embryos?</p> <p><input type="radio"/> No</p> <p><input type="radio"/> Yes</p> <p><i>If YES, please explain how the human embryos will be used in the project.</i></p> <p><input type="text" value="[Comment box]"/></p>

Activities excluded from funding

Activities that:

- aim at human cloning for reproductive purposes, or
- intend to modify the genetic heritage of human beings which could make such changes heritable (with the exception of research relating to cancer treatment of the gonads, which may be financed), or
- intend to create human embryos solely for the purpose of research or for the purpose of stem cell procurement, including by means of somatic cell nuclear transfer, or
- lead to the destruction of human embryos (for example, for obtaining stem cells)?

are excluded from funding. Does the proposal include any of these activities?

No

Yes

If YES, please explain.

[Comment box]

Do not significant harm principle

Is this proposal compliant with the 'Do no significant harm' principle?

Not applicable

Yes.

Partially

No

Cannot be assessed

If Partially/No/Cannot be assessed please explain.

[Comment box]

Exclusive focus on civil applications

Do the activities proposed have an exclusive focus on civil applications (activities intended to be used in military application or aim to serve military purposes cannot be funded)?

No

Yes

If NO, please explain.

[Comment box]

Artificial Intelligence
<p>Do the activities proposed involve the use and/or development of AI-based systems and/or techniques?</p> <p><input type="radio"/> No</p> <p><input type="radio"/> Yes</p> <p><i>If YES, the technical robustness of the proposed system must be evaluated under the appropriate criterion.</i></p>

3. COMMENTS

Overall comments
[Comment box]

[additional OPTION for CR:

]

Consensus meeting
Consensus meeting minutes
[Comment box]
Minority opinion
<p>Does this proposal have a minority opinion?</p> <p><input type="radio"/> No</p> <p><input type="radio"/> Yes</p> <p>If YES, please encode the names of dissenting evaluators and the reasons:</p> <p>[Comment box]</p>

[additional OPTION for ESR (for internal use – will not be included in the ESR sent to applicants):

]

Panel review
Consensus meeting minutes
[Comment box]
Proposal panel review minutes
[Comment box]

]

HISTORY OF CHANGES		
VERSION	PUBLICATION DATE	CHANGE
1.0	18.06.2021	Initial version (new MFF).